    ‘Sentence 1: The U.S. Food and Drug Administration  rejected ImClone ‘sori  December 2001 , saying the trial had been sloppily  conducted .         ‘Sentence 2: The Food and Drug Administration  ultimately denied ImClone ‘s drug application in    December 2001 , saying that an Erbitux clinical  trial was deficient .    